Quarterly ResultApr 27, 2026, 08:03 AM
APLM FY2025 Net Loss $(10.9)M; Revenue $8.5M; Vebreltinib IND H1 2027
AI Summary
Apollomics Inc. announced full-year 2025 financial results, reporting a net loss of $(10.9) million, a substantial improvement from $(53.9) million in 2024. Revenue for the year reached $8.5 million, primarily from a vebreltinib licensing agreement, compared to zero in the prior year, while operating expenses decreased by 64%. The company anticipates submitting an Investigational New Drug Application for accelerated approval of vebreltinib for second-line NSCLC treatment in the first half of 2027. This progress follows a strategic turnaround, including a new management team, significant cost reductions, and the resolution of legacy legal matters.
Key Highlights
- FY2025 net loss was $(10.9) million, significantly reduced from $(53.9) million in FY2024.
- FY2025 revenue was $8.5 million, up from $0 in FY2024, driven by a LaunXP licensing agreement.
- Operating expenses decreased by 64% year-over-year to $19.8 million in FY2025.
- Anticipate submitting an IND for accelerated approval of vebreltinib for NSCLC in H1 2027.
- Vebreltinib approved by China's NMPA for three indications, including two first-in-class.
- New management team appointed in September 2025, leading a strategic turnaround plan.
- Cash, cash equivalents were $3.3 million as of Dec 31, 2025; raised $4.1 million in PIPE financing.